|
. |
24 1/2 |
|
|
Subject |
Hyundai Pharm, Tranexamic Acid Topical Form Patent Application Completed |
Content |
(2015-10-14) On 14th, Hyundai Pharm announces that they submitted foreign patent application for HTB-003 (TA topical), world¡¯s first topical technology, on September 28th in 10 countries (U.S.A, Canada, Brazil, Mexico, Japan, china, India, Indonesia, Thailand, Vietnam). HTB-003 (TA topical) is a new topical chemical form indicated for melasma and freckles, and it is the world¡¯s first topical tranexamic acid product with changes in its use and form.
Tranexamic acid, a plasmin inhibitor, is known to be effective in freckles treatment which inhibits growth of melanin formative cell, melanin pigment, or arachidonic acid. Also, HTB-003 (TA topical) uses Hyundai¡¯s Transdermal Accelerating Technology which enables tranexamic acid to rapidly delivered into skin and sustain for a period of time. Not only that, it is known that
HTB-003(TA topical), as whitening management concept, is recognized with its value in improvement from cosmetics to a pharmaceutical grade product with its safety and efficacy much improved; it is expected its market to be much increased due to its uniqueness in dual use in monotherapy and surgery
Yeong Hak Kim, president of Hyundai Pharm, states that ¡°With patent application submission, I believe it was a good opportunity for HTB-003 (TA topical) to be recognized, the world¡¯s first topical formulation technology, value and its excellence. We plan to further improve this technology to develop much effective and safe freckles treatment.¡±
|
Date |
2015-10-14 |
|
|
|
|
|